Niddk: service: intravenous stable isotope glucose (6,6 deuterated glucose) for metabolic research. Nonseverable
Ended Awarded Last action
- Contract number
- 75N94025F00003
- Awardee
-
Pine Pharmaceuticals LLC UEI TCJXKNYD6WL5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $69,466
Award facts
- Contract value 100% obligated
- $69,466.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Tonawanda, NY 14150, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $69,466 |
About this award
The National Institute of Diabetes and Digestive and Kidney Diseases awarded a delivery order valued at $69,466.32 to Pine Pharmaceuticals LLC on August 14, 2025, for the provision of intravenous stable isotope glucose (6,6 deuterated glucose) to support metabolic research initiatives. This non-severable delivery order, structured as a firm fixed-price contract, is scheduled for completion by May 31, 2026, with performance taking place at Pine Pharmaceuticals' facility in Tonawanda, New York. No set-aside designation was applied to this award. Pine Pharmaceuticals, an FDA-registered 503B outsourcing facility headquartered in Tonawanda, specializes in pharmaceutical compounding and the production of specialized pharmaceutical products critical to biomedical research, with over 37 years of operational history serving federal agencies.
This delivery order is issued under Pine Pharmaceuticals' larger $7.27 million single-award indefinite delivery contract with NIDDK, designated as a total small business set-aside, with performance extending through September 29, 2029. The parent contract supports the provision of metabolic isotopes for research studies conducted across multiple HHS agencies. Pine Pharmaceuticals has demonstrated extensive federal contract activity with NIDDK and other NIH institutes, consistently delivering specialized intravenous stable isotopes and compounded pharmaceutical products. The company also maintains a separate indefinite delivery contract with the Department of Veterans Affairs valued at $136,915 for 503B compounding pharmaceutical services through March 31, 2026, further establishing its role as an established prime contractor for ongoing federal pharmaceutical supply requirements.
Quick answers
Who was awarded contract 75N94025F00003?
75N94025F00003 was awarded to Pine Pharmaceuticals LLC by National Institute of Child Health and Human Development (National Institutes of Health) on August 14, 2025.
How much is contract 75N94025F00003 worth?
The government has obligated $69,466 on 75N94025F00003.
Which agency awarded contract 75N94025F00003?
National Institute of Child Health and Human Development (National Institutes of Health) awarded 75N94025F00003, with funding from National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health).
Is contract 75N94025F00003 an order under another contract?
Yes. 75N94025F00003 is a delivery order under 75N94024D00003, an indefinite delivery contract.
Was contract 75N94025F00003 competed?
The extent of competition for 75N94025F00003 was competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award